Why I’d buy Neil Woodford’s favourite dividend stock AstraZeneca plc in 2018

2018 could be the year that AstraZeneca plc’s (LON: AZN) turnaround finally starts to take hold.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a mixed year for Neil Woodford’s favourite stock AstraZeneca (LSE: AZN). Heading into the year, investors and analysts alike were skeptical about the pharmaceutical and biopharmaceutical company’s prospects. But cautious buying sent the shares up to a high of 5,500p at the end of June — ahead of the release of data from the company’s lung cancer study of its immunotherapy Imfinzi.

Unfortunately when the data was published, it didn’t live up to expectations and the shares slumped back down to 4,300p.

However, a robust set of third quarter figures, posted at the beginning of November, have helped investors regain confidence in Astra’s outlook. 

For the third quarter, the group posted core earnings per share of $1.12, ahead of the average City estimate of $1.09, while revenues were $6.2bn versus expectations of $6bn. What’s more, Astra’s CEO Pascal Soriot declared alongside these figures that earnings for the full-year would be “towards the favourable end” of the previously guided “low to mid teens percentage decline,” which pleased investors and analysts. 

Turnaround gaining traction

As stated, Astra is Neil Woodford’s favourite dividend stock and the star fund manager has allocated around 8% of both his Woodford Equity Income and Income Focus funds to the pharmaceutical giant, making it the largest holding for both funds. Woodford is betting that Astra’s treatment pipeline will yield results in the years ahead and the stock’s 4%-plus dividend yield is here to stay. 

And I believe that Woodford will be rewarded in 2018, a year that’s set to be a transformational one for Astra. Indeed, even though City analysts are expecting the firm to report a mid-single-digit decline in earnings per share for the year, the firm’s outlook should start to improve towards the end of 2018 as a string of new treatments take up the slack from declining Crestor sales.

To the beginning of November, the firm had received approvals for four new drugs and sales of existing products were growing faster than expected within emerging markets. There are still plenty of other new cancer-fighting drugs in the company’s pipeline and as these are approved for sale, the group will slowly move towards its goal of doubling revenues by 2023. 

Time to buy? 

By the end of 2018, investors should have much more clarity on Astra’s outlook and management should be able to establish if the company will return to growth in 2019. I believe it’s highly likely that growth will return in 2019 based on the recent product approvals and a slower than expected decline in Crestor sales. 

The one downside is that shares in Astra are relatively expensive. The stock currently trades at a forward P/E of around 17. In comparison, peer GlaxoSmithKline trades at a forward earnings multiple of just under 12. This valuation does not leave much room for error if the company fails to live up to expectations.

That said, I would argue that Astra deserves a high multiple due to its treatment pipeline, which has been labelled as one of the best in the sector by City analysts.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »